Privi Speciality Chemicals Limited

Privi makes aroma chemicals. These are the individual molecules that go into fragrances for soaps, detergents, shampoos and fine perfumes. Privi does not make the finished fragrance. It sells the ingredients to the companies that do: Givaudan, IFF, Symrise, P&G, Reckitt and BASF. Exports are 65 to 70 percent of revenue, into more than 40 countries. The portfolio is over 75 products made from about 60 raw materials. Six plants at Mahad in Maharashtra and one at Jhagadia in Gujarat, 48,000 tonnes of installed capacity, running at about 90 percent. Incorporated 1985. Mahesh Babani is chairman and managing director. Promoters hold 60.6 percent.

The cost advantage sits in the raw material. Most aroma chemical makers start from Gum Turpentine Oil, which is tapped from live pine trees and swings hard on price and availability. Privi processes that route and also processes Crude Sulphate Turpentine, a waste by-product of the wood pulp industry that costs 15 to 20 percent less and is far steadier in supply. Only four companies in the world have advanced CST processing. Privi also runs both alpha and beta pinene lines off it, which most peers cannot.

About 70 percent of revenue sits under annual contracts written back to back against input sourcing. Raw material moves are passed to the customer rather than absorbed. Crude-linked inputs are only 15 to 18 percent of purchases.

PRIGIV is the 51 percent joint venture with Givaudan, equity accounted. It makes 42 products sold exclusively to Givaudan. Q1 FY27 revenue was Rs 18 cr at a 14 to 15 percent EBITDA margin.

Q1 FY27 against Q1 FY26: total income Rs 681.42 cr, up 20.0 percent. EBITDA Rs 167.47 cr, up 18.7 percent, at a 24.58 percent margin. PAT Rs 83.2 cr against Rs 61.46 cr, up 35.4 percent. That is the ninth straight quarter at roughly 25 percent EBITDA margin.

The balance sheet moved further than the P&L. The working capital cycle came down to 108 days from 141 days a year ago. Working capital intensity was 32.3 percent of revenue in FY26 against 41.8 percent in FY25. Net debt at 30 June 2026 was Rs 865 cr, which is 1.29 times EBITDA and 0.57 times equity. Quarterly ROE was 21.7 percent and ROCE 22.72 percent. ICRA assigned an AA (Stable) rating on 30 June 2026 against a Rs 300 cr term loan carrying a 7.6 percent coupon out to FY34.

The timing point is capacity. Privi is at 90 percent utilisation, so it cannot grow without adding tonnes, and three phases of tonnes land in sequence over the next 30 months. The first commercialises this month.

Phase 1, September 2026. Capacity goes from 48,000 to 54,000 tonnes on existing flagship products. This slipped one quarter from June and is now days away. Volume sold before it is made, given where utilisation sits.

Merger completion, by March 2027. Privi Fine Sciences and Privi Biotechnologies fold into the listed company. The scheme is filed with NCLT after no-objection from both exchanges. Adds about 6,000 tonnes and simplifies the group into one entity.

Phase 2, September 2027. Capacity to 66,000 tonnes.

Maltol and ethyl maltol, contributing from H2 FY28. These are made from furfural, which Privi will make from corn cob. More than 95 percent of world supply is Chinese today and India imports the ethyl maltol it uses in pharmaceuticals. Privi is building roughly one fourth of global capacity and will be the only company anywhere integrated from the cob upwards. Management sizes this vertical at Rs 1,000 cr and more of revenue. Ethyl maltol goes in as a pharma intermediate and needs no approval; maltol is a flavour and needs GMP certification, which the plants are being built to.

Musk T, cyclopentanone and ten to eleven unnamed specialty molecules under Phases 2 and 3. Mechanically complete by mid-2027, revenue from H2 FY28.

PRIGIV scale-up, with Rs 50 cr of fresh equity going in jointly for the next expansion. Two strategic alliances are underway and undisclosed. Management has closed the door on further joint ventures and will instead do exclusive molecule development for named customers.

The estimates below are mine, not the company's. They assume the 20 percent revenue growth the chairman calls a minimum, EBITDA margin held at 24.6 percent against management's stated 24.6 to 25 percent, PAT margin near 12.5 percent of total income with depreciation and interest rising against Rs 850 to 900 cr of capex spread over three years, and 3.91 cr shares with no dilution.

Enterprise value is Rs 14,146 cr including the Rs 865 cr of net debt, which is 21 times TTM EBITDA and under 13 times FY29E.

At Rs 3,400 the price asks for one thing: that Privi keeps doing what it has already done for nine quarters. Nothing in the table above needs a new product to work. It needs 20 percent volume-and-price growth on capacity that is already being built, at a margin the company has held through a raw material cycle that swung both ways. Earnings compounding at 20 percent with the multiple standing still is a 20 percent return, which clears the hurdle on its own. Management's own 5,000 cr revenue and 1,000 cr plus EBITDA target lands in FY30 on this trajectory and earlier if the new molecules ramp on time, and on that plan EPS is close to Rs 170. The maltol vertical is not in my numbers at all. It is the free option.

Gross margin fell to 44.2 percent in Q1 FY27 from about 51 percent a year ago. Raw material cost is back inside the normal 52 to 55 percent band after a year of unusually cheap input and unusually good contract pricing in calendar 2025. Management calls this normalisation rather than deterioration, and the 24.6 percent EBITDA margin held only because other expenses fell. The comparison gets easier from Q2 because H2 FY26 already carried the higher raw material cost.

Alpha-pinene made from GTO is at a historic high, up 70 to 80 percent in five months. The contracted 70 percent of the book is covered back to back. The balance is exposed until contracts reset annually.

Execution. Phase 1 has already slipped one quarter. Rs 850 to 900 cr of capex over three years, with Rs 500 to 600 cr of it debt funded. Maltol is a new chemistry on a new feedstock into a new customer set, against Chinese incumbents holding 95 percent share.

Working capital. Inventory is around Rs 700 cr on transit times of 60 to 130 days. The cycle has improved but growth will keep consuming cash.

Promoter holding has fallen roughly 13 percentage points over three years, including a block sale in December 2025 in the Rs 2,835 to 2,850 range.

EBITDA margin below 22 percent for two straight quarters with no raw material explanation. Phase 2 slipping past September 2027, or the specialty plants not mechanically complete by mid-2027. Working capital cycle back above 130 days. Net debt to EBITDA above 2.0. The merger not closing this financial year.

TenetFour Research. Educational analysis only. Not investment advice or a recommendation to buy, sell, or hold any security. Author may hold a position. Readers are responsible for their own decisions.